NCT02529813 - CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 16, 2015

Primary Completion Date

November 8, 2021

Study Completion Date

November 8, 2021

Conditions

Acute Biphenotypic LeukemiaAcute Lymphoblastic LeukemiaBlasts 5 Percent or More of Bone Marrow Nucleated CellsCD19 PositiveMinimal Residual DiseaseNon-Hodgkin LymphomaSmall Lymphocytic LymphomaStage III Chronic Lymphocytic LeukemiaStage IV Chronic Lymphocytic Leukemia

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Tisagenlecleucel

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston